Inhaled Mometasone to Promote Reduction in Vasoocclusive Events

Trial Profile

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Mometasone (Primary)
  • Indications Respiration disorders; Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Nov 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.
    • 17 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top